Dominik Escher

Dominik is a founding partner of Pureos and a co-founder and Executive Chairman of CDR-Life. He is also president of the Swiss Biotech Association. Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to maturity, delivering multiple clinically successful products (e.g., Brolucizumab). Dominik obtained his PhD in Molecular Biology from the University of Zurich.